COLD ANTIBODY-MEDIATED AUTOIMMUNE HEMOLYTIC ANEMIA IN A PATIENT WITH OVERLAP SYNDROME OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH SJOGREN’S SYNDROME

INDIRA BAIRY¹, ANUPAMBERWAL², CHARANTHEJREDDY V³, MUKHYAPRANAPRABHU³

¹Department of Microbiology, Melaka Manipal Medical College, Manipal Campus, Manipal Academy of Higher Education, Manipal, Karnataka, India. ²Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. ³Department of Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. Email: ???

ABSTRACT

Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder commonly seen in females characterized by multisystem inflammation with the production of an array of antibodies. Hematological disturbances are common in SLE specifically autoimmune hemolytic anemia (AIHA) which results from the development of autoantibodies directed against antigens on the surface of patient’s own red blood cells. Here, we present a rare case of a 50-year-old female patient presenting with cold antibody-mediated AIHA.

Keywords: Autoimmune, Rituximab, Anemia.

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease commonly affecting women. SLE is a systemic autoimmune disorder characterized by multisystem inflammation with the production of an array of antibodies. Serum nuclear antibodies (antinuclear antibody [ANA]) are found in nearly all individuals with active SLE [1]. Autoimmune hemolytic anemia (AIHA) in SLE is usually mediated by warm immunoglobulin G anti-erythrocyte antibodies [2]. However, here, we report a female patient who was a known case of SLE, presented with cold antibody-mediated AIHA.

CASE REPORT

A 50-year-old woman presented to the department of medicine with dysphagia and passage of dark stools for 1 week. Dysphagia started 1 year back, and she was diagnosed as SLE overlap syndrome (SLE Sjogren’s syndrome and Raynaud’s phenomenon). She was started on steoids, after which the symptoms subsided for 2–3 months. Dysphagia started again for 1 week. Dysphagia started 1 year back, and she was diagnosed as SLE Sjogren’s syndrome. She was referred to our tertiary care hospital. Dysphagia and was referred to our tertiary care hospital. The patient complained of the phenomenon). She was started on steroids, after which the symptoms subsided for 2–3 months. Dysphagia started again for 1 week.

On examination, the patient was conscious and well oriented. Pallor was present, and there were no icterus, no clubbing, and no lymphadenopathy. Cyanosis of the fingers of the left hand was present. Her blood pressure was 110/70 mmHg, pulse 84 beats/min, respiratory rate 18/min, temperature 98°F, and SpO₂ 98% on room air. Her chest was clear, and the abdomen was soft, non-distended, and non-tender with no organomegaly. Cardiovascular system examination was normal.

Investigations

Her initial laboratory workup revealed peripheral smear showing spherocytosis. Serum bilirubin: Total - 1.41 mg/dl, direct - 0.09 mg/dl, indirect - 1.32 mg/dl, alkaline phosphatase - 73 IU/L (normal <130 IU/L), alanine aminotransferase - 17 IU/L (normal <40 IU/L), aspartate aminotransferase-63 IU/L (normal <40 IU/L), erythrocytes sedimentation rate - 60 mm/h, serum albumin - 4.21 g%, hemoglobin - 2.4 g/dl, total white blood cell - 8800/mm³, differential count - PMN 79.9/L, 12.6/E 2.2/M 4.7%, and platelet count - 309,000/mm³. Peripheral smear showed extensive red blood cell (RBC) clumping as shown in Fig. 1.

ANA immunofluorescence on human epithelial type 2 and rat liver cells showed nucleus granular pattern (+++) with a titer of >1:320. The ANA profile showed Ro-52 (+++), dsDNA ++, Sm (+), and SS-B (+). Antineutrophil cytoplasmic antibody immunofluorescence was negative.

Treatment

The patient was on methotrexate 15 mg/week for joint pain for 1 year. Initially, she was treated with prednisolone 1 mg/kg, but the patient continued to have hemolysis, and there was no improvement. Then, after review of literature, rituximab was considered as an option. The patient was treated for SLE-related intravascular hemolysis. Three units of packed RBC (PRBC) transfusions were given under warmer in view of dropping hemoglobin. However, treatment with steroids proved ineffective and the patient required further blood transfusions for symptomatic anemia. Rituximab was initiated resulting in significant clinical improvement. Her hemoglobin improved from 3.8 g/dl to 12 g/dl. The patient was subsequently discharged from the hospital.

Outcome and follow-up

The patient was continued on rituximab as outpatient and did not require any further blood transfusions. Her follow-up hematocrit levels remained stable. Over 1 month follow-up course, she showed remarkable improvement in her symptomatology and other clinical parameters including normalization of her hemoglobin levels.

Received: 21 July 2018, Revised and Accepted: 25 October 2018

© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i2.28644
DISCUSSION

Most patients with SLE develop hematological abnormalities during their natural course of the disease. Anemia is found in about 50% of patients, and the most common is anemia of chronic disease, followed by iron deficiency anemia, AIHA, drug-related myelotoxicity, and anemia of chronic kidney disease [2].

Antibody-mediated RBC damage is one of the most common mechanisms of anemia in SLE, and it is almost always mediated by warm antibodies. Acquired deficiency of RBC CD55 and/or CD59 is associated with AIHA in SLE. Similar mechanism can cause autoimmune thrombocytopenia and lymphopenia. Immune-mediated marrow failure is another mechanism for anemia/pancytopenia. First line of treatment for AIHA is prednisone (1 mg/kg/day). Approximately 80% of patients will show a dramatic response after 3 weeks, or patients requiring above 15 mg/day for maintenance are absolute candidates for second-line drugs. In idiopathic AIHA, only proven next line treatment with short-term efficacy is rituximab and splenectomy.

Although extremely rare, cold antibody AIHA in SLE has been reported [3,4]. Binding of antibodies to RBCs activates the classical pathway of the complement system leading to the formation of membrane attack complex and intravascular hemolysis. On the other hand, if classic pathway is ineffective, RBCs are opsonized with complement proteins (particularly, C3b and C4b) which enhance phagocytosis in the liver and spleen, presenting as extravascular hemolysis. In the present case, the hemoglobin level was low suggesting intravascular hemolysis. The peripheral blood smear confirmed the diagnosis.

Rituximab has been shown to be very efficacious in the past for AIHA with SLE refractory to conventional therapy [5]. Rituximab is also known to maintain long-term remission rate in patients with primary cold agglutinin AIHA [6,7] and showed rituximab to be extremely effective and safe therapeutic alternative in patients with intractable and severe AIHA. We used rituximab as our second-line agent. To the best of our knowledge, this is, perhaps, the first case report of CA-AIHA in a patient with overlap syndrome of SLE and Sjogren’s syndrome.

AUTHORS’ CONTRIBUTIONS
Dr. Indira Bairy - Edited the manuscript
Dr. Anupam Berwal - Prepared the manuscript
Dr. Charan - Did workup on the case
Dr. Mukhyapranaprabhu - Managed the case and also reviewed the manuscript.

REFERENCES